Merck & Company (MRK)

$91.45 +0.50 (0.55%)
Market Cap 225.74B
Revenue (ttm) 64.17B
Net Income (ttm) 17.12B
EPS (ttm) N/A
PE Ratio 10.03
Forward PE 9.66
Profit Margin 26.68%
Debt to Equity Ratio 0.77
Volume 13,218,900
Avg Vol 12,082,656
Day's Range N/A - N/A
Shares Out 2.48B
Stochastic %K 87%
Beta 0.34
Analysts Sell
Price Target $102.45

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as liv...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 908 740 4000
Address:
126 East Lincoln Avenue, Rahway, United States
brimsted87
brimsted87 Nov. 13 at 6:58 AM
https://stocktwits.com/news-articles/markets/equity/moon-lake-therapeutics-stock-sparks-retail-frenzy-ahead-of-new-york-summit-traders-see-nonstop-catalysts-through-2026/cLPBscUREdx $TSLA $NVDA $PFE $MRK $BYND time to get involved
0 · Reply
Spicy_Trade
Spicy_Trade Nov. 13 at 6:10 AM
SpicyTrade Merck & Company, Inc. ( $MRK ) daily stock analysis https://youtu.be/JWVhy77i2Rc?si=RG3cEW1hVKR5OtXn
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 13 at 5:16 AM
💎 LiquidTheta® Live Actionable Trade Asset: $MRK Contracts: $MRK December 18, 2026 $95 Calls Scale in: $8.30- $10.15 Scale out: $32.29-$55.35 Profit Potential : 104% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 12:56 AM
$MRK trade plan: Market Context: The last close at $90.57 is near the 60D high of $91.00, indicating a potential resistance level. The RSI of 59.97 suggests that the stock is approaching overbought territory but is not yet overextended, allowing for further upside potential. Directional Bias: The stock shows a bullish trend, supported by the MA30 (86.62) and MA50 (84.74) being below the current price, indicating upward momentum. The price is above both moving averages, reinforcing a positive outlook. Suggested Entry: Consider entering a long position above $90.75 to confirm upward momentum. Stop: Place a stop-loss at $88.40, just below the recent support level. Targets: First target at $91.50, slightly above the 60D high, and a second target at $93.00, allowing for further gains if momentum continues. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
up2moon
up2moon Nov. 12 at 10:04 PM
Lilly 1T MC tomorrow, next week? Congrats! This should be good for the whole sector and maybe gives a little push to other, 'smaller' players, if one can call them that. It is mind boggling that $LLY is currently valued more than e.g. $ABBV, $MRK, $PFE and $BMY, all still coined 'big pharma', combined.
1 · Reply
zaxby99
zaxby99 Nov. 12 at 8:45 PM
$MRNA BUYOUT! BUYOUT! BUYOUT! $MRK
0 · Reply
billymike
billymike Nov. 12 at 8:41 PM
$MRNA $MRK or $PFE ?
1 · Reply
StockElementCorporation
StockElementCorporation Nov. 12 at 8:12 PM
$MRK - Target posted on chart. FOLLOW US FOR MORE LEVELS & ALERTS 🚨
0 · Reply
Galen_Bulls
Galen_Bulls Nov. 12 at 7:50 PM
$MRK NXXT earnings could be today. Funds know intrinsic value and are locking size before headlines. Vanguard 1,049,265 and NY State Common 28,100
0 · Reply
Molllz_smartmoney
Molllz_smartmoney Nov. 12 at 6:33 PM
🚨 $MRK April 2026 $100 Calls: More Size Coming In! Looks like traders are adding again to those $MRK $100 call contracts today, building on yesterday’s spike. Open interest (OI) will confirm if these are fresh buys or flips—check tomorrow’s OI update to see if the size sticks! Watching for that conviction to keep heating up.
0 · Reply
Latest News on MRK
Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript

Nov 10, 2025, 12:21 PM EST - 2 days ago

Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial

Nov 9, 2025, 5:00 PM EST - 3 days ago

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

Nov 8, 2025, 2:30 PM EST - 4 days ago

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

Merck and Blackstone enter research agreement to develop cancer therapy for $700 million

Nov 4, 2025, 7:00 AM EST - 9 days ago

Merck and Blackstone enter research agreement to develop cancer therapy for $700 million

BX

Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)

Nov 4, 2025, 6:50 AM EST - 9 days ago

Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)

Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody

Nov 4, 2025, 6:45 AM EST - 9 days ago

Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody

Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.

Nov 3, 2025, 6:45 AM EST - 10 days ago

Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.

Top 10 High-Yield Dividend Stocks For November 2025

Nov 2, 2025, 7:12 AM EST - 11 days ago

Top 10 High-Yield Dividend Stocks For November 2025

ACN CMCSA EOG NEE PAG PAYX SPY

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (Nov. 2025)

Nov 1, 2025, 8:15 AM EDT - 12 days ago

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (Nov. 2025)

ADP AEG AMH APH ARCC CAG CIB

Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 1:36 PM EDT - 13 days ago

Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript

My Top 10 High-Yield Picks For November 2025: One Yields 9%+

Oct 30, 2025, 1:33 PM EDT - 13 days ago

My Top 10 High-Yield Picks For November 2025: One Yields 9%+

ARCC BAC BMO C CVS CVX JPM

Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook

Oct 30, 2025, 12:24 PM EDT - 13 days ago

Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook

Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge

Oct 30, 2025, 9:20 AM EDT - 13 days ago

Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Oct 30, 2025, 7:09 AM EDT - 14 days ago

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

VTRS XRAY

Merck Profit Rises on Strong Keytruda Demand

Oct 30, 2025, 6:41 AM EDT - 14 days ago

Merck Profit Rises on Strong Keytruda Demand

Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit

Oct 30, 2025, 6:38 AM EDT - 14 days ago

Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit

Merck posts higher third-quarter sales as Keytruda growth offsets drop from Gardasil

Oct 30, 2025, 6:33 AM EDT - 14 days ago

Merck posts higher third-quarter sales as Keytruda growth offsets drop from Gardasil

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

Oct 30, 2025, 6:30 AM EDT - 14 days ago

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

Merck Reports Earnings Under Shadow of Keytruda Patent Cliff. What to Expect.

Oct 29, 2025, 4:30 PM EDT - 14 days ago

Merck Reports Earnings Under Shadow of Keytruda Patent Cliff. What to Expect.

The setup on earnings beyond tech

Oct 29, 2025, 2:19 PM EDT - 14 days ago

The setup on earnings beyond tech

KLAC NOW SPGI

Merck, Eisai discontinue late-stage study for liver cancer therapy

Oct 29, 2025, 7:59 AM EDT - 15 days ago

Merck, Eisai discontinue late-stage study for liver cancer therapy

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

Oct 29, 2025, 7:00 AM EDT - 15 days ago

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

Oct 29, 2025, 6:45 AM EDT - 15 days ago

European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings

Oct 28, 2025, 10:40 AM EDT - 15 days ago

Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings

ABBV GILD LLY

Merck Partners with Promega to Advance 3-D Cell Drug Discovery Technologies

Oct 28, 2025, 9:16 AM EDT - 15 days ago

Merck Partners with Promega to Advance 3-D Cell Drug Discovery Technologies

Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy

Oct 28, 2025, 6:45 AM EDT - 16 days ago

Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy

Merck-Eisai's cancer drug combo meets one main goal in late-stage study

Oct 28, 2025, 6:43 AM EDT - 16 days ago

Merck-Eisai's cancer drug combo meets one main goal in late-stage study

Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

Oct 28, 2025, 6:30 AM EDT - 16 days ago

Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study

Oct 27, 2025, 6:45 AM EDT - 17 days ago

U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study

Merck Q3 Earnings Preview: Issues That Will Dominate The Agenda

Oct 24, 2025, 4:24 PM EDT - 19 days ago

Merck Q3 Earnings Preview: Issues That Will Dominate The Agenda

eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience

Oct 23, 2025, 11:55 AM EDT - 20 days ago

eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience

These low-risk stocks could be a profitable answer to this volatile earnings season

Oct 23, 2025, 10:52 AM EDT - 20 days ago

These low-risk stocks could be a profitable answer to this volatile earnings season

AMGN BMY CVS GD GIS HQY HRL

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025

Oct 23, 2025, 6:45 AM EDT - 21 days ago

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer

Oct 23, 2025, 6:00 AM EDT - 21 days ago

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer

Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer

Oct 21, 2025, 7:00 AM EDT - 23 days ago

Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults

Oct 21, 2025, 6:45 AM EDT - 23 days ago

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults

My Top 3 Pharma Stocks

Oct 20, 2025, 11:38 AM EDT - 23 days ago

My Top 3 Pharma Stocks

AKRO BMY ETNB LLY NVO PFE SPY

US Supreme Court won't revive mumps vaccine antitrust case against Merck

Oct 20, 2025, 9:52 AM EDT - 23 days ago

US Supreme Court won't revive mumps vaccine antitrust case against Merck

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

Oct 20, 2025, 8:45 AM EDT - 23 days ago

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

Merck begins construction of $3 billion manufacturing facility in Virginia

Oct 20, 2025, 7:07 AM EDT - 24 days ago

Merck begins construction of $3 billion manufacturing facility in Virginia

Merck breaks ground on $3B manufacturing plant in Virginia

Oct 20, 2025, 6:56 AM EDT - 24 days ago

Merck breaks ground on $3B manufacturing plant in Virginia

Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia

Oct 20, 2025, 6:45 AM EDT - 24 days ago

Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

Oct 18, 2025, 10:35 AM EDT - 25 days ago

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

Oct 18, 2025, 10:30 AM EDT - 25 days ago

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen

Oct 18, 2025, 6:00 AM EDT - 26 days ago

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen

Merck: Earnings Outlook Steady, Keytruda Now Has Some Breathing Room

Oct 16, 2025, 8:00 AM EDT - 4 weeks ago

Merck: Earnings Outlook Steady, Keytruda Now Has Some Breathing Room

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer

Oct 16, 2025, 6:45 AM EDT - 4 weeks ago

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer

Germany's Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets

Oct 16, 2025, 2:00 AM EDT - 4 weeks ago

Germany's Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets

Germany's Merck tweaks mid-term healthcare unit guidance

Oct 16, 2025, 1:04 AM EDT - 4 weeks ago

Germany's Merck tweaks mid-term healthcare unit guidance

Merck: A Golden Buying Opportunity

Oct 15, 2025, 3:43 PM EDT - 4 weeks ago

Merck: A Golden Buying Opportunity

brimsted87
brimsted87 Nov. 13 at 6:58 AM
https://stocktwits.com/news-articles/markets/equity/moon-lake-therapeutics-stock-sparks-retail-frenzy-ahead-of-new-york-summit-traders-see-nonstop-catalysts-through-2026/cLPBscUREdx $TSLA $NVDA $PFE $MRK $BYND time to get involved
0 · Reply
Spicy_Trade
Spicy_Trade Nov. 13 at 6:10 AM
SpicyTrade Merck & Company, Inc. ( $MRK ) daily stock analysis https://youtu.be/JWVhy77i2Rc?si=RG3cEW1hVKR5OtXn
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 13 at 5:16 AM
💎 LiquidTheta® Live Actionable Trade Asset: $MRK Contracts: $MRK December 18, 2026 $95 Calls Scale in: $8.30- $10.15 Scale out: $32.29-$55.35 Profit Potential : 104% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 12:56 AM
$MRK trade plan: Market Context: The last close at $90.57 is near the 60D high of $91.00, indicating a potential resistance level. The RSI of 59.97 suggests that the stock is approaching overbought territory but is not yet overextended, allowing for further upside potential. Directional Bias: The stock shows a bullish trend, supported by the MA30 (86.62) and MA50 (84.74) being below the current price, indicating upward momentum. The price is above both moving averages, reinforcing a positive outlook. Suggested Entry: Consider entering a long position above $90.75 to confirm upward momentum. Stop: Place a stop-loss at $88.40, just below the recent support level. Targets: First target at $91.50, slightly above the 60D high, and a second target at $93.00, allowing for further gains if momentum continues. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
up2moon
up2moon Nov. 12 at 10:04 PM
Lilly 1T MC tomorrow, next week? Congrats! This should be good for the whole sector and maybe gives a little push to other, 'smaller' players, if one can call them that. It is mind boggling that $LLY is currently valued more than e.g. $ABBV, $MRK, $PFE and $BMY, all still coined 'big pharma', combined.
1 · Reply
zaxby99
zaxby99 Nov. 12 at 8:45 PM
$MRNA BUYOUT! BUYOUT! BUYOUT! $MRK
0 · Reply
billymike
billymike Nov. 12 at 8:41 PM
$MRNA $MRK or $PFE ?
1 · Reply
StockElementCorporation
StockElementCorporation Nov. 12 at 8:12 PM
$MRK - Target posted on chart. FOLLOW US FOR MORE LEVELS & ALERTS 🚨
0 · Reply
Galen_Bulls
Galen_Bulls Nov. 12 at 7:50 PM
$MRK NXXT earnings could be today. Funds know intrinsic value and are locking size before headlines. Vanguard 1,049,265 and NY State Common 28,100
0 · Reply
Molllz_smartmoney
Molllz_smartmoney Nov. 12 at 6:33 PM
🚨 $MRK April 2026 $100 Calls: More Size Coming In! Looks like traders are adding again to those $MRK $100 call contracts today, building on yesterday’s spike. Open interest (OI) will confirm if these are fresh buys or flips—check tomorrow’s OI update to see if the size sticks! Watching for that conviction to keep heating up.
0 · Reply
StreetwiseReports
StreetwiseReports Nov. 12 at 6:20 PM
Breakthrough Pill Cuts Bad Cholesterol by Nearly 60% in Major Trials https://ow.ly/6QxU50XqGH8 Merck & Co. Inc. ($MRK:NYSE) announced that its investigational oral PCSK9 inhibitor, enlicitide, achieved significant LDL-C reductions in two pivotal Phase 3 studies presented at the American Heart Association Scientific Sessions. The once-daily pill demonstrated efficacy comparable to injectable therapies, marking a major step forward in cholesterol management.
0 · Reply
gti10001
gti10001 Nov. 12 at 5:15 PM
Merck ($MRK ) is crushing it with Keytruda pipeline! Strong Buy consensus – analysts see $145.80 target. From $86.75 now? That's 68% upside! Load up before pharma rally. #MRK #BuyNow #gtindicators
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Nov. 12 at 4:11 PM
$MRK Technicals here are slowly turning bullish 50 DMA curling … That looks like a golden cross forming
0 · Reply
iTrade_Price
iTrade_Price Nov. 12 at 3:21 PM
$MRK - nice strength today
0 · Reply
Turbofueled
Turbofueled Nov. 12 at 3:06 PM
$LEXX $NVO $PFE $MTSR $MRK
0 · Reply
SSmicrocap
SSmicrocap Nov. 12 at 2:46 PM
$MRK $100 time
0 · Reply
theoptionsplug
theoptionsplug Nov. 12 at 2:41 PM
$MRK $1.X.1M block order for the January $90 calls 🟩
0 · Reply
complexoptions
complexoptions Nov. 12 at 2:36 PM
$MRK most undervalued among BP ?
0 · Reply
iQuicky
iQuicky Nov. 12 at 2:14 PM
$MRK 100$ in Christmas
0 · Reply
RichardBarsom
RichardBarsom Nov. 12 at 1:40 PM
$WGRX Einstein Rx guys this is a $MRK project! Huge!
1 · Reply
lucgallo
lucgallo Nov. 12 at 8:58 AM
$IMMP FWIW, saw some pretty wild option activity in Merck ($MRK) yesterday. Over 30,000 April $100 calls bought, most of them right after the open. Open interest was only 698 Had this weird vision/dream that it might be tied to a Merck buyout announcement for Immutep ($IMMP). Probably just wishful thinking... but hey, one can dream 😅
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 12 at 7:43 AM
💎 LiquidTheta® Live Actionable Trade Asset: $MRK Contracts: $MRK December 18, 2026 $95 Calls Scale in: $7.65- $9.35 Scale out: $29.75-$51.00 Profit Potential : 309% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply